North America Insulin Market Size & Outlook, 2024-2030
North America insulin market, 2018-2030 (US$M)
Related Markets
North America insulin market highlights
- The North America insulin market generated a revenue of USD 8,664.8 million in 2024.
- The market is expected to grow at a CAGR of 2.3% from 2025 to 2030.
- In terms of segment, insulin analog was the largest revenue generating type in 2024.
- Insulin Analog is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 8,664.8 million |
| Market revenue in 2030 | USD 9,510.3 million |
| Growth rate | 2.3% (CAGR from 2025 to 2030) |
| Largest segment | Insulin analog |
| Fastest growing segment | Insulin Analog |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Insulin Analog, Human Insulin |
| Key market players worldwide | Novo Nordisk A/S ADR, Eli Lilly and Co, Sanofi SA, United Laboratories International Holdings Ltd, Biocon, Wockhardt, Boehringer Ingelheim Pharma, Tonghua Dongbao Pharmaceutical, Julphar |
Other key industry trends
- In terms of revenue, North America region accounted for 44.6% of the global insulin market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,094.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Insulin Market Scope
Insulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America insulin market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to insulin market will help companies and investors design strategic landscapes.
Insulin analog was the largest segment with a revenue share of 85.81% in 2024. Horizon Databook has segmented the North America insulin market based on insulin analog, human insulin covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of diabetes is anticipated to boost demand for insulin, thereby, driving the market growth. According to the CDC, around 37.3 million people are living with diabetes in the U.S., of which, 28.7 million are diagnosed and 8.5 million are undiagnosed cases.
Furthermore, about 96 million people aged 18 years and older have prediabetes. Thus, initiatives undertaken by key players to raise awareness about disease and insulin treatment can benefit patients & physicians, which is expected to increase market penetration over the forecast period.
For instance, in December 2019, Eli Lilly and Company initiated a campaign to increase awareness about insulin cost-saving options as per patients’ requirements.
Reasons to subscribe to North America insulin market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America insulin market databook
-
Our clientele includes a mix of insulin market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America insulin market , including forecasts for subscribers. This continent databook contains high-level insights into North America insulin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America insulin market size, by country, 2018-2030 (US$M)
North America Insulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
